TYRATECH, INC. • ANNUAL REPORT 2011 • PAGE 9
Human Health & Well-Being
We are focused on three areas in this category:
• Head & Body Lice control: In the first half of 2012 we initiated a clinical trial of our head lice product,
VaMousse!™. The clinical trial is a randomized, parallel study to evaluate two TyraTech formulations to a
leading product currently on the market. We are very encouraged by the positive results to date
which indicate that our safe formulations are giving results superior to products currently on the market and
are effectively controlling synthetic-resistant lice and nits. We expect to complete our clinical trial in
the second half of 2012 and will provide a further update to you at that time. We believe our product will
address a global market well in excess of $600 million, a market that has lacked innovation for some time.
• Personal Insect Repellents: We are developing a range of personal insect repellents featuring TyraTech
Nature's Technology® to meet the global demand for safe and highly effective alternatives to synthetic
products. Test results to date have been encouraging and we are confident that our formulation will meet the
programme's objectives which are to develop an efficient, safe and cost effective natural insect repellent.
We view this as a highly attractive and accessible market opportunity which we believe to be worth in excess
of $1 billion globally.
• Human Functional Food to control the level of harmful intestinal parasites: we have a strategic partnership with
Kraft Foods for the development of functional foods. Test results of the technology continue to be promising as
the companies continue to work closely together to identify ways in which to accelerate the monetisation of
this project.
Animal Health
We have identified several product opportunities in the Animal Health market. Initially, efforts are focused on
the flea and tick market for companion animals and the biting fly market for horses and cattle, which we have
estimated to have a market size in excess of $400 million. We believe that the significant advances we have made
in our personal and surface repellent projects will accelerate development of high value products for the Animal
Health market.
To date, TyraTech has invested in excess of $50 million to build its technology platform and develop products for
high value markets. The Directors believe the Company is in a strong position to progress the commercialization of
several products to serve markets that are demanding innovation and increased safety.
